Erwin Schreiner

Title: The Innovative Mind of Erwin Schreiner: A Spotlight on Patents and Contributions

Introduction: Erwin Schreiner, hailing from Kundl, Austria, is an inventive force with a notable portfolio of six patents. His contributions primarily focus on pharmaceutical compositions and processes, showcasing his expertise in the field of drug development.

Latest Patents: Among his latest patents, Schreiner has developed multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor. This innovative invention relates to crystalline compounds combining vadadustat and L-proline, along with processes for their preparation. Notably, this pharmaceutical composition is aimed at treating and preventing anemia in patients suffering from end-stage renal disease (ESRD) and chronic kidney disease (CKD). Additionally, he holds a patent for a process for the preparation of crystalline ridinilazole using acid addition salts. This invention outlines the method of creating pure ridinilazole, utilizing these salts as vital process intermediates.

Career Highlights: Throughout his illustrious career, Erwin Schreiner has worked with esteemed companies such as Sandoz AG and Lek Pharmaceuticals d.d. His innovative spirit and dedication to advancing pharmaceutical science have made significant impacts on the industry.

Collaborations: Schreiner's work has benefited from collaborations with notable colleagues, including Marijan Stefinovic and Christoph Langes. These professional relationships highlight the importance of teamwork and shared expertise in driving innovation forward.

Conclusion: Erwin Schreiner exemplifies the essence of a modern inventor, leveraging his knowledge to create groundbreaking pharmaceutical solutions. His contributions not only enhance therapeutic options for patients but also affirm his role as a significant figure in the realm of innovations and patent achievements.